Surrogate endpoints for overall survival in lung cancer trials: a review (Q38841987)

6 September 2017

title

Surrogate endpoints for overall survival in lung cancer trials: a review (English)

1 reference

6 September 2017

Frédéric Fiteni

1

1 reference

6 September 2017

Virginie Westeel

series ordinal

2

1 reference

6 September 2017

Franck Bonnetain

series ordinal

3

1 reference

6 September 2017

publication date

12 April 2017

1 reference

Expert Review of Anticancer Therapy

6 September 2017

published in

1 reference

6 September 2017

volume

17

1 reference

6 September 2017

issue

5

1 reference

6 September 2017

page(s)

447-454

1 reference

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Statistical evaluation of surrogate endpoints with examples from cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung C

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

Surrogate Endpoints And FDA’s Accelerated Approval Process

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1316196

10.1080/14737140.2017.1316196

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference